News

March 30, 2017March 30, 2017

Kadmon’s Preclinical Findings Support ROCK Inhibition as Potential PF Therapy

Kadmon Holdings reported preclinical findings showing the significance of the ROCK signaling pathway in the development of pulmonary fibrosis (PF), supporting the development of drugs that inhibit this pathway as a ... Read more

March 28, 2017March 28, 2017

Phase 3 Study of Ofev as Treatment for Progressive Fibrosing Lung Diseases Now Enrolling Patients

Idiopathic Pulmonary Fibrosis, News

The first patient has been enrolled in Boehringer Ingelheim’s Phase 3 clinical trial investigating the effectiveness and safety of Ofev (nintedanib) in progressive fibrosing interstitial lung diseases (PF-ILD). ILD encompasses a ... Read more

March 27, 2017March 27, 2017

HMGB1 Protein Causes Lung Airways of People with Severe Asthma to Narrow, EU Study Finds

Asthma, News

Researchers have discovered that the active form of the HMGB1 protein narrows the lung airway in people with severe asthma, providing a potential target for new treatments. Their study, “HMGB1 is upregulated ... Read more

March 24, 2017March 24, 2017

Galapagos Starts Trial of Therapy It Hopes Becomes Part of Triple-Combination CF Treatment

Cystic Fibrosis, News

Galapagos has started a Phase 1 clinical trial of its novel potentiator GLPG3067 for cystic fibrosis (CF). It is the second Phase 1 trial the company is conducting. The other one ... Read more

March 23, 2017March 23, 2017

New Research Reveals How IPF Treatments Ofev and Esbriet Work

Idiopathic Pulmonary Fibrosis, News

Researchers from Germany have identified how Ofev (nintedanib) and Esbriet (pirfenidone) work — two FDA-approved drugs for the treatment of idiopathic pulmonary fibrosis (IPF). The study, titled “A Novel Antifibrotic Mechanism ... Read more

March 22, 2017March 22, 2017

Sound Pharma Awarded $1.6M to Test Therapy for Hearing Loss in CF Patients

Cystic Fibrosis, News

Sound Pharmaceuticals was recently awarding funding up to $1.6 million to support the early development of its lead drug candidate SPI-1005 for cystic fibrosis (CF) patients who are taking the ... Read more

March 21, 2017March 21, 2017

New ‘Pulmonary Fibrosis Information Guide’ Released by PF Foundation

Idiopathic Pulmonary Fibrosis, News

The Pulmonary Fibrosis Foundation (PFF) recently released its updated “Pulmonary Fibrosis Information Guide,” a resource to provide patients and families with updated information about pulmonary fibrosis (PF), treatment options, and methods of ... Read more

March 20, 2017March 20, 2017

AstraZeneca, Circassia Partner on COPD Medications Tudorza and Duaklir for U.S. Market

COPD, News

AstraZeneca and Circassia Pharmaceuticals will joint develop and market Tudorza and Duaklir — inhaled drugs to treat chronic obstructive pulmonary disease (COPD) — in the United States. Tudorza received Food and Drug ... Read more

March 17, 2017March 17, 2017

Aeolus Pharmaceuticals’ AEOL 20415 Protected Lungs Against Infection in CF Animal Model

Cystic Fibrosis, News

Results from a new animal study show that Aeolus Pharmaceuticals’ anti-microbial compound, AEOL 20415, may protect the lungs from infections in cystic fibrosis (CF). In the study, conducted in a ... Read more

March 16, 2017March 16, 2017

Galecto’s TD139 Shows Promise in IPF Patients, Clinical Trial Shows

Idiopathic Pulmonary Fibrosis, News

Galecto Biotech has completed a Phase 1b/2a clinical trial that indicated its inhaled therapy candidate TD139 shows promise in treating idiopathic pulmonary fibrosis (IPF) patients. TD139 is an inhibitor of galectin-3, ... Read more